PBLA vs. SNGX, CLVR, DRUG, YMTX, SONN, LIPO, CPHI, ARTL, ENSC, and ONCO
Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Soligenix (SNGX), Clever Leaves (CLVR), Bright Minds Biosciences (DRUG), Yumanity Therapeutics (YMTX), Sonnet BioTherapeutics (SONN), Lipella Pharmaceuticals (LIPO), China Pharma (CPHI), Artelo Biosciences (ARTL), Ensysce Biosciences (ENSC), and Onconetix (ONCO). These companies are all part of the "pharmaceutical preparations" industry.
Soligenix (NASDAQ:SNGX) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Panbela Therapeutics has a net margin of 0.00% compared to Panbela Therapeutics' net margin of -1,025.66%. Panbela Therapeutics' return on equity of -198.36% beat Soligenix's return on equity.
Soligenix currently has a consensus price target of $3.00, indicating a potential upside of 852.38%. Panbela Therapeutics has a consensus price target of $500.00, indicating a potential upside of 124,900.00%. Given Soligenix's higher possible upside, analysts plainly believe Panbela Therapeutics is more favorable than Soligenix.
Soligenix has higher revenue and earnings than Panbela Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
3.6% of Soligenix shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 1.4% of Soligenix shares are owned by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Soligenix received 260 more outperform votes than Panbela Therapeutics when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 66.67% of users gave Panbela Therapeutics an outperform vote.
Soligenix has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
In the previous week, Soligenix had 8 more articles in the media than Panbela Therapeutics. MarketBeat recorded 8 mentions for Soligenix and 0 mentions for Panbela Therapeutics. Panbela Therapeutics' average media sentiment score of 0.26 beat Soligenix's score of 0.00 indicating that Soligenix is being referred to more favorably in the media.
Summary
Soligenix beats Panbela Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Panbela Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Panbela Therapeutics Competitors List
Related Companies and Tools
